The proposed acquisition consideration represents an equity value for Myovant of $2.4 billion and an enterprise value of $2.5 billion.
The booster vaccination trial is still ongoing and further data will provide more information around safety and efficacy.
The company will address the observations within a stipulated timeline working with the regulators
Sildenafil for Oral Suspension (RLD Revatio) had estimated annual sales of US $64 million in the US
The companies have also initiated a Phase 1/2/3 study NCT05543616 to evaluate the safety, tolerability, and immunogenicity of different doses
The companies will leverage their respective proprietary technology platforms
Sitagliptin is an active ingredient in JANUVIA, JANUMET and JANUMET XR
One in two women with advanced ovarian cancer has an HRD-positive tumor
The plant at Raleigh, North Carolina, USA owned by Aurolife Pharma has received an establishment inspection report (EIR)
NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.
Subscribe To Our Newsletter & Stay Updated
